Faizan Zubair
Co-Founder & CEO
PhD in Chemical & Biomolecular Engineering. Ten years in pharma and startups.
Canine OA first
Injectable Biomaterials for Canine Osteoarthritis
We are developing an injectable biomaterial for canine osteoarthritis, with the goal of supporting damaged cartilage and improving mobility.
Early development · Initial experimental validation planned
The opportunity
A focused starting point.
A meaningful mobility problem.
Osteoarthritis can make everyday movement painful for dogs. Our goal is to develop a new option to support joint health and mobility.
Canine OA is our first intended market. We are preparing initial laboratory studies to evaluate feasibility and performance.
$364M
Estimated U.S. canine OA market in 2024
Recoil calculation: $776.97M U.S. companion-animal OA market × 46.9% canine share. Market context, not a Recoil revenue forecast.
Source: Grand View Research, 2025 reportDevelopment
A clear path to the first evidence.
We are designing our initial validation studies. Each milestone is intended to inform the next development decision.
- 01
Planned
Laboratory feasibility
Evaluate initial candidates and establish evidence to guide development.
- 02
Planned
Preclinical evaluation
Assess safety and performance to inform the next research milestone.
- 03
Future, evidence-dependent
Canine studies
Use laboratory findings and veterinary input to determine readiness, study design, and meaningful clinical endpoints.
Future opportunity
Canine OA may inform human OA development.
Positive canine evidence could guide future human research. Human applications would require their own development program and regulatory pathway.
The team
Experience across science, materials, and translation.
Founders and operating team
Joseph Kuo
Co-Founder & COO
PhD in Immunology and MBA. Business development in life sciences.
Christian Croxton
Biomaterials Lead
Experience in biomaterials and implantable medical devices.
Advisors
Paul Laibinis
Scientific Advisor
Chair and Professor of Chemical & Biomolecular Engineering at Vanderbilt. Surface chemistry and self-assembly.
Vanderbilt profileKelly Smith
Regulatory Advisor
Regulatory strategy and chemistry, manufacturing, and controls (CMC).
For investors and collaborators
Help fund the next evidence milestone.
We are raising pre-seed capital to support initial laboratory and preclinical studies. Contact us for a non-confidential overview of the company and financing plan.